

APPENDIX A
"CLEAN" VERSION OF EACH PARAGRAPH/SECTION/CLAIM
37 C.F.R. § 1.121(b)(ii) AND (c)(i)

CLAIMS (with indication of amended or new):

Sub B1
Amended 1. In a method of hormone replacement therapy in a host by administering an effective amount of a selective estrogen receptor modulator to the host to control and regulate estrogenic impact on estrogen sensitive tissues and organs, the improvement which comprises additionally administering an agent which exhibits progestogenic activity to the host in an amount effective to modulate the side effects of the selective estrogen receptor modulator.

B2
Amended 4. The method of claim 1 wherein the agent which exhibits progestogenic activity is an antiprogesterin.

Amended 10. The method of claim 1 wherein the agent which exhibits progestogenic activity expresses both androgenic and progestogenic activity.

B3
Amended 11. The method of claim 10 wherein the agent which exhibits progestogenic activity comprises the combination of an androgen and a progestin.

Amended 12. The method of claim 10 wherein the agent which exhibits progestogenic activity is a single material which expresses both activities.

Amended 13. The method of claim 12 wherein the agent which exhibits progestogenic activity is danazol or levonorgestrel.